Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Abivax (ABVX) over the last 4 years, with Q3 2025 value amounting to $72.5 million.

  • Abivax's Total Non-Current Liabilities changed N/A to $72.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.5 million, marking a year-over-year change of. This contributed to the annual value of $75.5 million for FY2024, which is 7293.09% up from last year.
  • As of Q3 2025, Abivax's Total Non-Current Liabilities stood at $72.5 million.
  • Abivax's Total Non-Current Liabilities' 5-year high stood at $84.1 million during Q2 2024, with a 5-year trough of $17.2 million in Q4 2022.
  • In the last 4 years, Abivax's Total Non-Current Liabilities had a median value of $71.3 million in 2025 and averaged $61.0 million.
  • As far as peak fluctuations go, Abivax's Total Non-Current Liabilities soared by 15196.22% in 2023, and later tumbled by 2516.58% in 2025.
  • Abivax's Total Non-Current Liabilities (Quarter) stood at $17.2 million in 2022, then skyrocketed by 151.96% to $43.4 million in 2023, then soared by 73.86% to $75.5 million in 2024, then fell by 3.9% to $72.5 million in 2025.
  • Its Total Non-Current Liabilities was $72.5 million in Q3 2025, compared to $62.9 million in Q2 2025 and $71.3 million in Q1 2025.